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ABSTRACT 
The objective of the current study was to investigate the processability of Aquasolve™ 
HPMC-AS LG via hot-melt extrusion, and to examine the effect of pressurized carbon dioxide (P-
CO2) on the physico-mechanical properties of Efavirenz (EFA)-loaded extrudates (EXT). EFA is 
as a poorly water-soluble drug and HPMC-AS LG was chosen as a carrier for this study. To 
optimize the process parameters and formulations, various physical mixtures were prepared with 
the following composition: EFA (30-40-50% w/w) and HPMC-AS LG (70-60-50 % w/w) 
respectively. Physical mixtures were extruded through the co-rotating twin-screw extruder (16mm 
Prism Euro Lab, Thermo Fisher Scientific) utilizing a standard screw configuration. P-CO2 was 
injected into eight zone of extruder using a high-pressure regulator connected to flexible stainless-
steel hose with armor casing.  The thermal characterization of extrudates was obtained by using 
differential scanning calorimetry (DSC) and thermal gravimetric analysis (TGA). A scanning 
electron microscopy (SEM) was conducted to study morphology and porosity of formulations. The 
macroscopic morphology changed to a foam-like structure, resulting in increased specific surface 
area, porosity and dissolution rate. Thus, HPMC-AS LG extrudates with P-CO2 injection exhibited 
relatively higher dissolution rate than extrudates without P-CO2. Additionally, HPMC-AS LG was 
able to physically and chemically stabilize the amorphous state of high-loading EFA in the 
extrudates. The milling efficiency was improved for extrudates with P-CO2 injection due to porous 
nature and morphology changes.  
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1. INTRODUCTION 
 
In the last two decades, hot melt extrusion has evolved as one of the most promising 
pharmaceutical processing technology. [1]. HME technology has several advantages over 
conventional pharmaceutical processing technologies including short processing time, continuous 
process, does not demand the use of water or toxic organic solvents[2,3]. HME is generally utilized 
for solubility enhancement[5]. HME has also revealed significant value for manufacturing various 
dosage forms such as pellets, tablets, transmucosal products as well as various usages such as 
controlled release formulations, targeted drug delivery including taste masking formulations.[6].  
HME pharmaceutical applications have not been wholly appreciated, mainly  attributed to the 
complex design of HME as well as the non-predicted performance of materials during the HME 
process[7].  
Recently, several HME-enabled products have commercially approved, which gives this 
technology more interest in the pharmaceutical industry. However, it is hard to ignore the fact that 
many of pharmaceutical polymeric systems shown thermal and/or viscoelastic challenges during 
HME process. Moreover, active pharmaceutical ingredients exhibit their own individual 
limitations such as high melting temperatures and/or the low degradation temperatures [8].The 
physicochemical properties of the active pharmaceutical ingredient (API), including the glass 
transition and the melting point temperatures, the degradation temperatures, and the miscibility or 
solubility of the API in the polymer carrier, have to be considered carefully, since they have a 
significant effect on the hot-melt extrusion processes as well as the final output[9–12].
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 The polymer carrier system is regularly the principal component within the formulation. 
Thus, the physicochemical properties of the polymer carrier including molecular weight, viscosity, 
Tg, etc., can have the significant influence on HME processing conditions and the performance of 
the HME drug products [13,14]. The degradation temperature and viscoelastic properties of the 
polymeric carrier system are two major factors and must be well-thought-out during HME process 
[15]. Therefore, the fully realizing of thermal and viscoelastic properties of the various 
drug/polymer mixtures help to establish the HME processing parameters (such as extrusion 
temperatures, screw speed, feeding rate, and motor load) as well as provide insight into the 
properties of the final output [16]. 
More than 50% of common pharmaceutical polymers for HME processing could not be 
processed as neat by HME. The reason of this problem attributes that those polymers reveal 
viscosities exceeding the defined maximum viscosity limit within HME processing window. 
Normally, this issue could be solved by plasticizing these polymers through adding the APIs, in 
which reducing the viscosities to be smoothly extrudable. When the APIs can’t adequately 
plasticize the polymeric carriers, in this case, it requires an alternative formulation or processing 
strategies to utilize these carriers. Moreover, the feasibility of thermally unstable APIs becomes 
less when the polymeric carriers processing at high temperatures during HME processing window 
[8]. 
One of the strategies to process the polymers within acceptable processing conditions is 
addition of plasticizers [17]. Typically, plasticizers perform to increase the free volume between 
polymer chains, causing a depression of the Tg and the melt viscosity [18]. Normally, traditional 
plasticizers are utilized in a concentration between 5–30 % w/w of the extrudable physical 
mixtures[19–21]. The additional 5–30% w/w to the total weight of formulations, is a drawback, 
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since that may be result in  large dosage forms [17]. Therefore, it would be necessarily to find an 
alternative to traditional plasticizers in pharmaceutical extrusion. Lately, supercritical carbon 
dioxide (sc-CO2), and subcritical (pressurized) carbon dioxide have been investigated as temporary 
plasticizer by reducing the HME processing temperatures without adding weight to the final 
formulations [22,23]. It has been examined that sc-CO2, or P-CO2 act as a foaming agent [24]. Thus, 
the increasing surface area and the porosity of the polymers resulting in enhanced dissolution [25]. 
HPMC-AS has been exhibited to be a very effective crystallization inhibitor in amorphous 
solid dispersions ASDs [26,27]. HPMC-AS polymers have a Tg of 120°C, however they regularly 
require extrusion temperatures in excess of 170°C, even with plasticization, to reduce the higher 
motor torque due to melt viscosity[28]. Then, these facts put HPMC-AS LG a desirable candidate 
for the current research to provide a fully understanding of the relationship between the physical 
and mechanical properties of physical mixtures of model drug and HPMC-AS LG to assess their 
suitability, as well as the correlation with the actual hot-melt extrusion process parameters. In this 
current study the effect of carbon dioxide as a foaming agent was examined, and understand the 
impact on the physico-mechanical properties and performance of the extrudates. 
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2. MATERIALS AND METHODS 
2.1. Materials 
 
Aquasolve™ Hydroxypropyl Methylcellulose Acetate Succinate HPMC-AS LG grade and 
Efavirenz (EFA), Ibuprofen (IBU), and Theophylline (THEO) were obtained as gift samples from 
Ashland Inc. (Wilmington, DE). Carbon dioxide (CO2) was supplied in gas cylinders (pure clean) 
from Airgas (Tupelo, MS). All other chemicals and reagents used in the present study were of 
analytical grade and obtained from Fisher Scientific (Fair Lawn, NJ). 
 
 
2.2. Methods  
2.2.1. Thermogravimetric analysis (TGA) 
 
TGA studies were performed for materials EFA and HPMC-AS LG to establish processing 
temperatures for extrusion and stability using a Perkin Elmer Pyris 1 TGA running Pyris manager 
software (PerkinElmer Life and Analytical Sciences, 719 Bridgeport Ave., Connecticut, USA). 
Five to seven milligrams of the sample were weighed in an aluminum pan and heated from 25°C 
to 200°C at 10°C/min heating rate under nitrogen atmosphere. 
2.2.2. Hot Melt Extrusion processing  
 
The co-rotating twin-screw intermeshing extruder (16mm Prism Euro Lab, Thermo Fisher 
Scientific, Waltham, MA) was utilized to perform the HME processes. The extruder is divided into 
10-barrel zones adjacent to the gravimetric feeder. Thermo Fisher Scientific standard screw 
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configuration was used for this study, which consists of four conveying zones and three mixing 
zones Carbon dioxide (CO2) was pressurized and injected into the extruder using a high-pressure 
regulator connected to flexible stainless-steel hose with armor casing. The other end of the hose 
was connected to the four-way connection, fitted with a pressure gauge, bleed valve, check valve 
(ball type for unidirectional flow of gas), with the latter being connected to the injection port at 
eight zone (conveying zone) of the extruder (Figure 1). Metering of P-CO2 was regulated using 
the regulator knob. The preliminary studies were conducted to determine the processing 
temperature of pure polymer over temperature range of 140 to 190 °C with 75 & 100 rpm. At 190 
°C extrusion was investigated in the presence of P-CO2. Similarly, the extrusion was investigated 
at 20%, 30%, 40% and 50% drug load with and without P-CO2 (data not shown). 
 
techniques 2CO-up of the combined HME/P-Schematic representation for the set. 1Figure  
 
2.2.3.  Physical mixture 
 
 After optimizing the HME process parameters and formulation, various physical mixtures 
were prepared with the following composition: EFA (30-40-50% w/w) and HPMC-AS LG (70-
60-50% w/w), respectively. The mixtures were blended using a V-shell blender (Maxiblend, 
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GlobePharma) at 25 rpm for 15 min. All the formulations mentioned in (Table 1) were studied and 
successfully extruded at the employed processing conditions. 
Table 1. Conditions and outcomes for optimized formulations during HME processes 
Formulations Processing  
Temperature 
(°C) 
Screw 
Speed 
(rpm) 
Barrel 
Torque 
(%) 
P-CO2 (PSI) P-CO2 
Injection 
Zone 
30% EFA/ 70% HPMC-AS LG EXT 140 100 46 300-400 Zone 8 
30% EFA/ 70% HPMC-AS LG EXT 140 100 46 - - 
40% EFA/ 60% HPMC-AS LG EXT 140 100 33 300-400 Zone 8 
40% EFA/ 60% HPMC-AS LG EXT 140 100 33 - - 
50% EFA/ 50% HPMC-AS LG EXT 140 100 27 300-400 Zone 8 
50% EFA/ 50% HPMC-AS LG EXT 140 100 27 - - 
30% EFA/ 70% HPMC-AS LG EXT 150 75 25-30 250-300 Zone 8 
30% EFA/ 70% HPMC-AS LG EXT 150 75 25-30 - - 
40% EFA/ 60% HPMC-AS LG EXT 150 75 20-25 250-300 Zone 8 
40% EFA/ 60% HPMC-AS LG EXT 150 75 20-25 - - 
50% EFA/ 50% HPMC-AS LG EXT 150 75 13-20 250-300 Zone 8 
50% EFA/ 50% HPMC-AS LG EXT 150 75 13-20 - - 
 These formulations were selected for further studies based on preliminary studies results. 
 
2.2.4. Milling Efficiency 
 
Prior to analysis, the HME extrudates were milled using a Fitz lab scale mill (Model L1A, 
Fitzpatrick, Perth Amboy, NJ) and particle size distribution and milling efficiency was studied 
using a vibrating sieve shaker (Gilson, performer III SS-3). The fraction below 600 m was utilized 
for further investigation. To study the milling efficiency of formulations before and after injection 
of P-CO2, 25 g of each melt extruded sample was milled for 3 min, 3000 rpm with a Fitz laboratory 
mill and particle size distribution was estimated using the vibrating sieve method. A set of sieves 
with known mesh size (respectively 75, 125, 250, 420, 600 and 840 m) and known tar weight, 
was placed on top of each other and known amount of the powder was placed in the top sieve. The 
whole stack was placed on a vibrating plate for 10 min at an amplitude of 1.5 mm after which each 
sieve was weight to obtain a particle size average distribution. 
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2.2.5. Drug content and degradation 
 
UV analysis was conducted to determine the uniformity of weight, drug content and 
degradation after extrusion with or without P-CO2 injection. The assay methods detailed in the 
USP were performed. The EFA content in the extrudates was determined by dissolving the 
contents in phosphate buffer solution (pH 6.8) and assayed spectrophotometrically against a blank 
comprising the buffer solution. The analysis was performed by UV spectrophotometer at 247 nm 
(Genesys 6, Thermo Fisher Scientific, Madison, WI, USA); a value at which the absorbance of the 
polymer is negligible. The percent drug content was compared to the calculated value. The 
experimental value was the average of triplicate.  
 
2.2.6. Dissolution studies 
 
In-Vitro dissolution testing was conducted on milled and 40# sieved extrudates samples 
and compared with a pure crystalline EFA. A USP dissolution apparatus II (Hanson SR8; Hanson 
Research, Chatsworth, CA, USA) was utilized with pH 6.8 phosphate buffer, at 37±0.5 °C, using 
a paddle rotating at 50 rpm, for 2 h. At predetermined time points, 2 mL of an aliquot was 
withdrawn and filtered through a filter tip 10 µm (Rockwood, TN, USA) and replaced with an 
equal volume of fresh dissolution medium after each sampling. EFA was assayed by UV 
spectrophotometer   maximum wavelength of 247 nm (Genesys 6, Thermo Fisher Scientific, 
Madison, WI, USA). All dissolution tests were carried out in triplicate and the mean and SD were 
reported. Student’s t-test was used for statistical analysis. 
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2.2.7. Solid State Characterization 
 
The nature of EFA in the extrudates was determined by using differential scanning 
calorimetry (DSC) and confirmed by powder x-ray diffraction (PXRD).  
2.2.7.1. Differential Scanning Calorimetry (DSC) 
 
The nature of pure EFA, pure HPMC-AS LG, physical mixture and its corresponding 
extrudates was assessed by DSC. The analysis was preformed using a DSC (TA instruments DSC 
25 Discovery series) coupled with a refrigerated cooling system. Samples of between 4 and 8 mg 
were weighed out using a Mettler Toledo scale. Samples were then placed in non-perforated 
aluminum pans, which were crimped before testing, with an empty crimped aluminum pan being 
used as a reference cell. Calorimetry scans were carried out from 50 to 200 °C for each sample. 
All DSC measurements were carried out at a scanning rate of 10 °C/min. Volatiles were removed 
from the purging head with nitrogen at a rate of 20 ml/min. Calibration of the instrument was 
preformed using indium as standard. After each scan was completed the melting points were 
analyzed and Trois manager software was used for the data analysis. 
2.2.7.2. Powder X-ray Diffraction Measurements (PXRD) 
 
The confirmation of crystallinity degree of pure EFA, pure HPMC-AS LG, EFA in the 
physical mixture and respective extrudates was investigated using, powder X-ray diffraction 
(PXRD) analyses using a Bruker D8 Focus X-ray diffractometer operated at voltage of 40 kV and 
a current of 40 mA. Powder was packed into the sample holder. Data for each sample were 
collected in the 2Θ angle range of 4–40° over 10 min in continuous detector scan mode. The 
process parameters were set as scan-step size of 0.02° (2Θ) and scan-step time of 0.3 s.  
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2.2.7.3. Scanning electron microscopy (SEM) 
 
The morphological characteristics and degree of porosity of extrudates at different drug 
loads of 30, 40 and 50 % with and without P-CO2 treatment was studied using SEM (JEOL JSM-
5600) that was operated at an accelerating voltage of 5 kV under analysis mode. Each specimen 
was fixed by conductive double-sided carbon adhesive tape and gold-sputter coated by a 
Hummer® 6.2 sputtering system (Anatech LTD, Springfield, VA) in a high-vacuum evaporator 
prior to the test to avoid electrostatic charging. Four magnificent (25, 50, 100, 250) were employed 
to give more accurate and clear understanding of results. 
2.2.8. Density and porosity  
 
True density of powdered extrudates for all the formulations as well as the pure polymer 
with and without P-CO2 was measured utilizing Micromeritics AccuPyc 1330 Gas pycnometer 
S/N-4011 (Norcross, GA). Prior to each run, calibration was performed. The sample was filled in 
10-cm3 sample cup and the weight of the sample was noted. True density was measured at an 
equilibration rate of 0.0050 psig/min and the number of purges was set to 10. Bulk and tapped 
density was calculated by measuring the volume of a 5 g milled extrudates in a 10 mL graduated 
cylinder. Porosity was calculated by the following equation [29]. 
% 𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 = 1 −  
𝐵𝑢𝑙𝑘 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
 × 100 
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3. RESULTS AND DISCUSSION 
3.1. HME processing 
 
The physicochemical properties of the API, and the polymeric carrier have to be 
considered carefully, since they have a significant effect on the hot-melt extrusion processes as 
well as the final output [9]. Therefore, the process parameters of hot-melt extrusion should be 
accustomed based on the physicochemical properties of each formulation component. 
Theoretically, as a rule the temperature of extrusion is required to set at 10-20 °C above the Tg of 
the polymers for flow consideration during the extruding process. In addition, there are many 
properties that could also be critical in HME process such as the melt viscosity of polymer, 
molecular weight, and miscibility. Furthermore, the plasticization effect of the drug on polymer 
may also plays an important role in extrudability of materials [16]. Many research studies have 
shown that the P-CO2 behaves as a plasticizer for some pharmaceutical polymers[17,23–
25,30,31].  
In this study, the temperature of extrusion and drug/polymer ratio have a major influence 
on HME process. During early stage of HME process optimizing, the extrudability of plain pure 
polymer was impossible when we set the temperature of the extruder below 160 °C since it led to 
reach the maximum level of motor load. At 160, 165, and 170 °C, the motor load was almost at 96 
%. This could be attributed to high viscosity of the polymer. To reduce the motor load, the speed 
of extruder was lowered to 75 rpm at all temperatures studied. The processing enhancement was 
very limited, and the process was restricted to go further. Moreover, P-CO2 did not indicate any 
sign of plasticizing effect on the polymer (reduction in the HME processing temperature and motor 
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load). Therefore, it was not logical to inject the P-CO2 at such high motor load. Quite the contrary, 
it exhibited rise in motor load even with increasing the temperature of extruder which would be 
explained as inability of the P-CO2 stream to penetrate the polymer. The relationship between the 
polymer, P-CO2, and temperature directed to inject the P-CO2 only at zone 8; neither zone 6 nor 
zone 4, which was very difficult to apply into the HME process. Table 2 lists the results of this 
relationship. Zone 4 and zone 6 provide relatively a long period of contact between the polymer 
and P-CO2 until they reach the extruder die. At zone 8 (Figure 1), the polymer and P-CO2 meet 
only at zone nine and ten of the extruder. Additionally, at zone 4 & 6 (Figure 1), the chance of 
back-pressure issue in extruder is high, which spread materials out of the feeding zone. However, 
it would be possible to inject the P-CO2 at least at zone 6 with increasing temperature to above 
190 °C. Nevertheless, the high temperature is not practical and having undesirable consequences 
upon formulation components and the extruder parts. Injection of P-CO2 at zone 8 was desirable 
to successfully produce a foaming, porous extrudates (Figure 1). 
3.2. Screening of appropriate API 
 
The type of drug, and its ratio in the formulations was very critical during the optimizing 
of the HME process. The low melting point drugs were supposed to be a suitable choice since 
those drugs could melt at low temperature and might act as plasticizing agents for HPMC-AS LG 
and provide smooth HME processing. Ibuprofen (Tm is about 78 °C) as a model drug provided a 
plasticizing effect as it was expected for the goal that it was selected for. However, the accumulated 
sticky materials caused a blockage at the feeding zone which is because of the low Tm of ibuprofen. 
Consequently, these sticky materials hindered obtaining a continuous HME process. It was 
concluded that not all low-melting point drugs act as plasticizers to HPMC-AS LG while injection 
of P-CO2. It was clearly observed that the steam of P-CO2 became hot after getting inside the 
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barrel, beside the temperature of extruder, which facilitated melting of ibuprofen and accumulating 
at the neck of funnel in the feeding zone. Additionally, a high melting point drug was investigated 
to avoid the blockage issue at the feeding zone. Theophylline (Tm is around 273 °C) was studied 
while HME processing. The initial results displayed that there is no blockage at the neck of the 
funnel at the feeding zone while processing theophylline through the HME. In the other hand, 
theophylline did not demonstrate significant persuasive impact on the HME process, because the 
motor load was high, even with the extruder temperature set up at 165 °C. This explains that there 
is no plasticizing effect of theophylline on HPMC-AS LG. Thus, intermediate melting point drug 
EFA (Tm is about 138 °C) was selected as the main model drug in this study. EFA showed very 
impressive influence on HPMC-AS LG via HME process. It overcame the blockage issue at the 
feeding zone and provided a strong plasticizing effect on HPMC-AS LG even with low ratio within 
the formulations (Table 2). While increasing the ratio of EFA, the motor load was going down, 
which means very desirable plasticizing effect without causing any blockage at the feeding zone 
during the HME process. With such an influence, the HME process would have a high range of 
flexibility and capacity to control the process for reaching the optimizable conditions. Moreover, 
The great character of polymers when they prove the high ability to solubilize a large amount of 
drug [32]. HPMC-AS LG has demonstrated its excellence by dissolving 50% of EFA in complete 
amorphous state as confirmed by DSC, and PXRD studies.  
3.3. Drug content and degradation 
 
TGA data demonstrated that all formulations utilized in this study were stable under the 
employed processing temperature (data not shown). UV analysis indicated acceptable uniformity 
of drug and drug content and no degradation of EFA as a function of temperature and pressure 
during the hot melt extrusion process with and without carbon dioxide injection. This confirmed 
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that the EFA was uniformly distributed in formulations with a higher yield. The combined HME/P-
CO2 processes showed relatively lower process loss. The average weights (± SD) of two series of 
20 capsules contents is equivalent to 100 mg of EFA. The reproducibility indicated by these results 
were considered to be satisfactory for the purposes of the present study. The analysis of drug 
content confirmed the theoretical value of the formulations, with values ranging from 96% to 
102%. 
3.4. Differential scanning calorimetry (DSC) 
 
DSC studies were conducted on all formulations including pure EFA and HPMC-AS LG, 
to ascertain the impact of P-CO2 during the processing of formulations and if it had any effect on 
their thermal properties.  
As it can be seen in Figure 2, the DSC thermograms of pure EFA showed apparent 
endothermic peak at around 140 °C. The sharp EFA peak was disappeared in all processed 
formulations except for their respective physical mixtures which shows less endothermic peak 
(less Tm) with less enthalpy of fusion. The absence of the peak indicates that the all processed 
formulations preserved the amorphous nature after HME coupled with P-CO2 processing. 
3.5. Powder X-ray Diffraction Measurements (PXRD) 
 
The diffraction patterns Figure 3 obtained from pure EFA, pure HPMC-AS LG, all processed 
formulations and their respective physical mixtures confirmed the amorphous nature of 
EFA and is in accordance with DSC data. Analysis of the XRD pattern obtained from pure EFA 
sample showed the several crystal peaks including the characteristic sharp and intense peak of 
EFA. As shown in Figure 3, the X-ray diffraction patterns of various samples, including processed 
extrudates, physical mixture (PM), and pure API showed characteristic peaks attributed to its 
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crystalline nature of EFA structure. On the other hand, the diffraction pattern of pure HPMC-AS 
LG did not show any Peaks (hallow band), which indicates that its polymeric structure is 
amorphous. In the physical mixture of EFA and HPMC-AS LG, there still were less intense peaks 
due to presence of partial EFA in crystalline form. In the X-ray pattern of the EFA–HPMC-AS LG 
extrudates, showed absence of characteristic peaks indicating the transformation of crystalline 
EFA into amorphous form and suggests that EFA was present in amorphous state. Finally, the 
diffractograms of the processed formulations before and after P-CO2 treatment assured that no 
modifications occurred after the treatment.  
3.6. Dissolution Studies 
 
To investigate the influence of P-CO2 injection within the polymeric matrix on EFA release from 
the HPMC-AS LG extrudates, In-Vitro dissolution study was conducted. HPMC-AS LG 
demonstrated enhancement of EFA dissolution rate, which is unidirectional to the increasing 
percentage of HPMC-AS LG in the formulations. Figure 4 shows the dissolution of EFA from 
various extrudates in the dissolution medium (pH 6.8). Extrudates at all drug loads released EFA 
higher than the pure EFA, presumably by generating a supersaturated state in the dissolution 
medium. The formulation of 30% EFA / HPMC-AS LG which processed by the assistance of P-
CO2 showed relatively greater EFA release than the other formulations (40%, 50% EFA / HPMC-
AS LG). This can be attributed to the media which is more specified for the HPMC-AS LG 
polymer and presence of polymer in a high percent. The order of improvement of drug dissolution 
for the formulations processed by this coupled technology (HME/P-CO2) was 30% EFA / HPMC-
AS LG EXT/ P-CO2> 40% EFA / HPMC-AS LG EXT/ P-CO2> 50% EFA / HPMC-AS LG EXT/ 
P-CO2. 
  
  
1
5 
Table 2. Results and conditions of investigating the extruder parameters, (polymer/ drug) ratio, and the type of the drug on HME 
processes with and without P-CO2 injection. 
Formulations 
 
Processing 
Temperature 
(°C) 
Screw 
Speed 
(rpm) 
Barrel 
Torque 
(%) 
P-CO2 
Injection Zone 
 
P-CO2 
(PSI) 
Back 
Pressure 
Feeding 
Zone 
Blockage 
HME 
Process 
4 6 8 
100% HPMC-AS LG 140 100 Maximum * - - - - - - Failed 
100% HPMC-AS LG 140 75 Maximum - - - - - - Failed 
100% HPMC-AS LG 140 100 Maximum - - - - - - Failed 
100% HPMC-AS LG 140 75 Maximum - - - - - - Failed 
100% HPMC-AS LG 150 100 Maximum - - - - - - Failed 
100% HPMC-AS LG 150 75 Maximum - - - - - - Failed 
100% HPMC-AS LG 150 100 Maximum - - - - - - Failed 
100% HPMC-AS LG 150 75 Maximum - - - - - - Failed 
100% HPMC-AS LG 160 100 98H.Q - - - - - - Successful 
100% HPMC-AS LG 160 75 88H.Q - - - - - - Successful 
100% HPMC-AS LG 170 100 88-90H.Q - - - - - - Successful 
100% HPMC-AS LG 170 75 82H.Q - - - - - - Successful 
100% HPMC-AS LG 190H.T 100 84-92H.Q - - - - - - Successful 
100% HPMC-AS LG 190H.T 75 80-90H.Q - - - - - - Successful 
100% HPMC-AS LG 190H.T 100 84-92H.Q - - √ 300-400 Low No  Successful 
100% HPMC-AS LG 190H.T 75 80-90H.Q - - √ 300-400 Low No  Successful 
80% HPMC-AS LG/% 20 EFA 140 100 54 - - - - - - Successful 
70% HPMC-AS LG/% 30 EFA 140 100 46 - - - - - - Successful 
60% HPMC-AS LG/% 40 EFA 140 100 33 - - - - - - Successful 
50% HPMC-AS LG/% 50 EFA 140 100 27 - - - - - - Successful 
80% HPMC-AS LG/% 20 EFA 150 75 44 - - - - - - Successful 
70% HPMC-AS LG/% 30 EFA 150 75 25-30 - - - - - - Successful 
60% HPMC-AS LG/% 40 EFA 150 75 20-25 - - - - - - Successful 
50% HPMC-AS LG/% 50 EFA 150 75 13-20 - - - - - - Successful 
80% HPMC-AS LG/% 20 EFA 140 100 54 - - √ 300-400 Low No  Successful 
70% HPMC-AS LG/% 30 EFA 140 100 46 - - √ 300-400 Low No  Successful 
60% HPMC-AS LG/% 40 EFA 140 100 33 - - √ 300-400 Low No  Successful 
50% HPMC-AS LG/% 50 EFA 140 100 27 - - √ 300-400 low No Successful 
80% HPMC-AS LG/% 20 EFA 150 75 44 - - √ 250-350 Low No  Successful 
70% HPMC-AS LG/% 30 EFA 150 75 25-30 - - √ 250-350 Low No  Successful 
60% HPMC-AS LG/% 40 EFA 150 75 20-25 - - √ 250-350 Low No  Successful 
50% HPMC-AS LG/% 50 EFA 150 75 13-20 - - √ 250-350 Low No  Successful 
*The motor reached the maximum level that was impossible to move on. 
Very limit success which means obtaining final product, but under very high motor load and temperature. 
H.T: very high temperature. 
H.Q: very high the motor load. 
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Figure 2. DSC thermograms of pure EFA, pure HPMC-AS LG, physical mixtures (PM) and extrudates (EXT) (with 
and without P-CO2).  
 
Interestingly, even though that the number of pores within the extrudates is higher and larger in 
50% drug load formulation (Figure 5) which might facilitate the drug release, but this can’t be 
compromised by the media which is highly preferable by the polymer. Furthermore, it was 
observed that HPMC-AS LG substitution level (LG grade) plays an important role in enhancing 
the solubility of EFA, which released faster and more completely from the EFA / HPMC-AS LG 
-grade extrudates (Figure 4). This result stems from EFA’s higher lipophilicity (logP of 4.6), which 
makes it dissolution-rate-limited, and from the higher succinoyl content of the LG-grade polymer, 
which offers higher hydrophilicity and thereby improves the dissolution rate. The same 
phenomenon has happened with a previous study. 
  
Pure EFA
Pure HPMC-AS LG
40% EFA /60% HPMC-AS LG PM
30% EFA/70% HPMC-AS LG PM
50% EFA /50% HPMC-AS LG PM
50% EFA /50% HPMC-AS LG EXT+P-CO2
30% EFA/70% HPMC-AS LG EXT
40% EFA/60% HPMC-AS LG  EXT
50% EFA/50% HPMC-AS Lg EXT
40% EFA /60% HPMC-AS LG EXT+P-CO2
30% EFA /70% HPMC-AS LG EXT+P-CO2
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Figure 3. A: PXRD diffractograms of pure crystalline EFA, B: PXRD diffractograms of pure HPMC-AS LG. C, F, 
and I: PXRD diffractograms of %30, %40, and %50 EFA/ HPMC-AS LG PM. D, G, and J: PXRD diffractograms of 
%30, %40, and %50 EFA/ HPMC-AS LG without-CO2. E, H, and K: PXRD diffractograms of %30, %40, and %50 
EFA/ HPMC-AS LG with P-CO2. 
 
The dissolution profiles are relatively higher for the CO2-treated materials. These extrudates were 
all amorphous, indicating that the release can be controlled as a function of the carbon dioxide 
treatment [25]. It was found that the HPMC-AS LG matrix governs the dissolution rate of the 
extrudates. When the molecules of HPMC-AS LG were dissolved, the EFA molecules dissolved 
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simultaneously because EFA molecules (up to 50%) were in amorphous form as shown in Figure 
2 and there was no need to overcome the lattice energy. Therefore, it has been confirmed that EFA 
was molecularly dispersed or nearly molecularly dispersed in the HPMC-AS LG matrix.   
The dissolution rate depends on the surface area of the material exposed to the dissolution 
media [33]. Although the foamed extrudates exhibit an increased surface area, the unmilled foams 
had significantly slower dissolution than regular ground extrudates. 
Moreover, although the porous matrix exhibited high surface area, the P-CO2 processed 
formulation (50% EFA / HPMC-AS LG) that has the lower density value and higher porosity 
(Table 3), and larger pore size (Figure 5-P, Q, R) has almost the same dissolution profile as the 
formulation without P-CO2 treatment (regular extrudates). This could be attributed to the particles 
being floated and accumulated on the surface of the media making these particles not fully 
accessible to all sides of the media resulting in limited contact between the two phases. Moreover, 
this can be attested by visually noticing the floating particles on the media surfaces throughout the 
dissolution study.  
In contrast, the other formulations; the P-CO2 processed formulations (30 & 40% EFA / 
HPMC-AS LG) sank into the dissolution media allowing the dissolution process to proceed faster 
through the fully accessible surfaces[34]. Since the P-CO2-treated extrudates are more 
hygroscopic[25], water penetrates faster within the matrix whereas slower in regular extrudates.  
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            Figure 4. In-Vitro release profile extrudates with and without P-CO2 
 
3.7. Scanning electron microscopy (SEM) 
 
The surface of all processed extrudates with P-CO2 treatment, shown in the SEM images 
of Figure 5, is quite different to the ones made by traditional extrusion process in which the 
extrudate is smooth compared to the foamed and porous extrudates. The specific surface area is 
clearly larger in the case of the foamed samples providing extended availability to the dissolving 
medium, which may increase the dissolution rate[34]. The internal and external porous structures 
of solid dispersions as seen in Figure 5 can alter the physico-mechanical properties of such a 
formulation.  
On the other hand, as shown in Figure 5, the matrix had mesh-like framework, denoting 
that P-CO2 penetrated during the process uniformly through HPMC-AS LG matrix. Thereby, these 
images suggest that homogeneous or heterogeneous porosity behavior might occur depending on 
drug load; i.e. with an increase in drug load up to (50%), homogeneous pores are formed during 
the processing of dispersions assisted by P-CO2 treatment while in (30% drug load), heterogeneous 
pores are formed during the processing of dispersions assisted by P-CO2 treatment. These pores 
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are dominating structures of HPMC-AS LG matrices. This can be attributed to the plasticizing 
effect of EFA, which leads to less viscous matrices and facilitate the penetration of P-CO2 
homogeneously throughout the matrix within the extruder barrel[34]. This can be confirmed by 
seeing images of regular extrudates wherein the smoother surfaces are accompanied with higher 
drug load (50%) whereas the rougher surfaces are accompanied with less drug load 30%. The 
smoothness of surfaces is a sign of the plasticizing effect of EFA on the polymer. This is in 
accordance with previous reports[23,35]. After injecting P-CO2 during the hot melt extrusion 
process and while the materials are exciting the extruder die, the pressure is expanded to 
atmospheric conditions, thereby, P-CO2 is released from the extrudates. This results in foam 
formation as explained by Lee et al.[36] and Park et al.[37]. Also, they illustrated that the pore size 
can be altered as a function of CO2 pressure and temperature. In addition, they obtained different 
morphologies ranging from a foamy-like structure to a fibrous-like structure[24]. 
 
3.8. Density and Porosity  
 
As seen in Table 3, all density values were decreased in case of formulations prepared by 
the aid of P-CO2. This would occur because of foamy and porous matrices that have been formed 
after P-CO2 treatment. Furthermore, porosity values are higher with samples prepared by the aid 
of P-CO2. This would allow for large surface area which leads to improved dissolution profile as 
well as tablet characteristics [23]. Also, it leads to high surface free energy that aids in stabilizing 
the amorphous form[38–41]. This low density and porous matrices might help in tablet 
characteristics which would be the theme of a continuing study. 
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Table 3. Bulk, tapped, true density and porosity of pure EFA, pure HPMC-AS LG, Physical 
Mixture (PM) and Extrudates (EXT) with and without P-CO2 (g/ml) 
Sample Name Bulk 
Density 
Tapped 
Density 
True 
Density 
%porosity 
EFA 0.225 0.338 1.450 84.440 
HPMC-AS LG 0.462 0.470 1.289 64.164 
30% EFA / HPMC-AS LG PM 0.369 0.447 1.416 73.912 
40% EFA / HPMC-AS LG PM 0.351 0.421 1.474 76.192 
50% EFA / HPMC-AS LG PM 0.317 0.404 1.532 79.261 
30% EFA / HPMC-AS LG EXT 0.598 0.629 1.347 55.631 
40% EFA / HPMC-AS LG EXT 0.612 0.668 1.362 55.066 
50% EFA / HPMC-AS LG EXT 0.620 0.652 1.381 55.111 
30% EFA / HPMC-AS LG EXT+P-CO2 0.461 0.493 1.350 65.874 
40% EFA / HPMC-AS LG EXT+P-CO2 0.494 0.519 1.357 63.617 
50% EFA / HPMC-AS LG EXT+P-CO2 0.350 0.466 1.382 74.681 
 
3.9. Milling Efficiency 
 
Influence of P-CO2 on milling efficiency for foamy structure extrudate was evaluated. Regular 
extrudates (i.e. without P-CO2 treatment) are glassy form in nature, which make them very difficult 
to mill to obtain a suitable particle size distribution. Consequently, the milling efficiency was 
determined with and without P-CO2 injection within HME process. Table 4 displays the results for 
this investigation. These results confirmed that the obtained amount of selected particle sizes 
(<600, 250, and 125 um) after milling process for formulation with P-CO2 larger than the 
corresponding formulations without P-CO2. Moreover, the resistance of milling machine during 
milling process for formulations with P-CO2 was less than the corresponding formulations without 
P-CO2. The enhancement of milling efficiency would be due the morphology changes into foam- 
like structure extrudates, as impact of P-CO2 injection.   
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Figure 5. SEM images of all Extrudates without, and with P-CO2; A, B, and C 30 % Extrudate (30% EFA / 70% 
HPMC-AS LG without P-CO2), D, E, and F 30 % Extrudate (30% EFA / 70% HPMC-AS LG with P-CO2), G, H, 
and I 40 % Extrudate (40% EFA / 60% HPMC-AS LG without P-CO2), J, K, and L 40 % Extrudate (40% EFA / 
60% HPMC-AS LG with P-CO2), M, N, and O 50 % Extrudate (50% EFA / 50% HPMC-AS LG without P-CO2), 
P, Q, and R 50 % Extrudate (50% EFA / 50% HPMC-AS LG with P-CO2) 
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Table 4. Results of the Milling Efficiency 
Sample Name Torque 
(Amps) 
Particles < 
600 um 
(%) 
 
Particles < 
250 um 
(%) 
 
Particles < 
125 um 
(%) 
 
30% EFA / HPMC-AS LG EXT 1.08 78.44 
 
9.57 1.03 
40% EFA / HPMC-AS LG EXT 0.85 84.99 
 
15.33 2.74 
50% EFA / HPMC-AS LG EXT 0.79 77.90 
 
3.37 0.98 
 
30% EFA / HPMC-AS LG EXT P-CO2 0.79 92.14 
 
14.88 1.97 
40% EFA / HPMC-AS LG EXT P-CO2 0.74 97.70 
 
24.41 4.75 
 
50% EFA / HPMC-AS LG EXT P-CO2 0.72 98.08 
 
13.64 
 
1.79 
 
Conclusion 
The comprehensive understanding of the relationship between the physico-chemical 
properties and physico-mechanical properties for physical mixtures of medium melting point EFA 
and higher Tg HPMC-AS LG, as well as the correlation with the actual hot-melt extrusion process 
parameters, and impact of P-CO2 successfully leads to obtain high-loading EFA within plasticized 
foamy matrix as a final output. HPMC-AS LG improved the release profile for all EFA-loaded 
extrudates with and without P-CO2 injection. However, EFA-loaded extrudates with P-CO2 
revealed relatively higher drug release than extrudates without P-CO2. The morphologic changes 
of extrudates as a foam-like structure after P-CO2 injection, resulting in an increased surface area 
and porosity. Thus, the milling efficiency of the extrudates was improved. HPMC-AS LG 
demonstrates a promising carrier to produce physically and chemically stable amorphous solid 
dispersion systems which are processed by HME. 
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